Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Aurobindo Pharma Ltd
| Q2 FY26 Earnings Conference Call
Summary : Aurobindo Pharma reported strong Q2 FY26 growth driven by US, Europe, and ARV segments, with a positive outlook on biosimilar commercialization, Pen-G ramp-up, and strategic acquisitions, despite some regulatory and competitive uncertainties.
Management Perspective positive : We remain confident about sustaining our growth momentum and driving value creation across all businesses. Our optimism is underpinned by expected volume expansion and reasonably stable pricing environment. We are firmly on track to comfortably support the 1 billion annual revenue milestone from Europe by the end of FY26. Last but not least, we are confident of achieving our internal margin target of 20%-21% for FY26.
Concall Report Analysis & Insights
Business Overview
- Consolidated revenues grew 6% year-on-year to ₹8,286 crores.
- EBITDA reached ₹1,678 crores with a 20.3% margin, up 7% year-on-year.
- Formulation business revenues increased 10% year-on-year to ₹7,325 crores.
- U.S. Formulation revenues were $417 million, with Oral Solid growing 6% quarter-on-quarter (excluding gRevlimid).
- European business delivered 18% year-on-year revenue growth to ₹2,480 crores (€243 million).
Future Growth Prospects
- Pen-G facility ramp-up is expected to significantly contribute to profitability.
- Commercialization of the biosimilar portfolio and biologic CMO progress are key growth drivers.
- Continued improvement in Injectable business is expected from supply ramp-up and new launches.
- The Lannett acquisition in the US will strengthen market position and expand the portfolio.
- Europe is on track to achieve $1 billion annual revenue milestone by end of FY26.
Management Insights
- Management is confident in sustaining growth momentum and driving value creation across all businesses.
- Optimism is underpinned by expected volume expansion and a reasonably stable pricing environment.
- The company remains focused on execution, operational excellence, and disciplined capital management.
- An internal margin target of 20%-21% for FY26 is expected to be achieved.
- Biosimilar development capabilities are proven, with FDA draft guidance streamlining approval processes.
Signs of Skepticism
- Uncertainty surrounds the implementation and impact of the Pen-G Minimum Import Price.
- The injectable business has not yet fully recovered to its pre-disruption sales levels.
- The China OSD facility is currently incurring a loss, targeting breakeven by Q3-Q4 FY26.
- The reported tax rate appears high due to non-recognition of tax credits for losses in some businesses.
- The company acknowledges not always being the first to launch in the increasingly competitive biosimilar market.
Risk Factors
- API business performance is subject to ongoing market dynamics and pricing environment.
- Injectable business has not fully returned to pre-disruption levels due to price decline.
- Reliance on government policy changes, like Minimum Import Price for Pen-G, introduces uncertainty.
- Potential delays in Eugia III reinspection could impact new injectable product launches.
- The biosimilar market is becoming more competitive with multiple players entering.
Good To Know
- The company launched 6 new products, 13 ANDAs, and received 7 final approvals in Q2.
- Pen-G operations commenced on July 1, 2025, producing 1,050 MT at 40-50% capacity.
- Net CapEx for the quarter was $106 million, focused on manufacturing and automation.
- Average finance costs declined to 4.7% compared to previous quarters.
- A second product contract was signed with MSD, expanding biosimilar collaboration.
Key Drivers
- Pen-G facility ramp-up to full capacity.
- Biosimilar portfolio commercialization and launches.
- Lannett acquisition completion in the US.
- Eugia III reinspection and approvals.
Key Analyst Discussions
Competitive Environment
- Overall US price erosion trends are close to neutral, with low single-digit erosion.
- Opportunistic products saw temporary better pricing/volume due to competitor disruptions.
- Entry barriers for biosimilars remain significant due to scientific complexity and GMP requirements.
- The company expects to be the third player for Omalizumab biosimilar in the US market.
- For Denosumab biosimilar, the company anticipates being in the second wave of launches.
Market Trends & Consumer Behavior
- China is expected to be a significant contributor to volume and EBITDA growth in emerging markets.
- The company plans to file GLP products across all markets next year from its Vizag plant.
- Small acquisitions are planned for the Indian market, but the company will not be aggressive.
Financial Highlights
- Pen-G plant is nearing breakeven and can increase production to 800 tons per month.
- EBITDA improvement (excluding Revlimid) was driven by sales growth, gross profit, and operating leverage.
- Gross margin increase is attributed to formulation products, European growth, and US product mix.
- The high reported tax rate is due to not taking tax credit on losses from certain businesses.
- CapEx is primarily for biosimilar capacity expansion and milestone payments, not major greenfield projects.
Product Composition
- Key pipeline products for US Injectables include those from Eugia III and Oncology oral solids.
- Injectables constitute about 10% of European revenue, with margins in the high teens.
- Lannett acquisition will add ADHD products to the US portfolio, pending FTC approval.
Strategic Considerations
- FDA accepted the Eugia III reinspection request, expected within 8 months.
- Current Pen-G production levels are sufficient to enable PLI benefit.
- Biosimilar pipeline is progressing well with planned EU/US filings for Denosumab, Omalizumab, and Tocilizumab.
- Large acquisitions are evaluated case-by-case based on synergies and new technological platforms.
- The China plant aims for triple-digit turnover within 2-3 years, with high productivity and good margins.